KR101750651B1 - Intraocular drug injection device having a drug residue prevention and a refill function - Google Patents

Intraocular drug injection device having a drug residue prevention and a refill function Download PDF

Info

Publication number
KR101750651B1
KR101750651B1 KR1020160010963A KR20160010963A KR101750651B1 KR 101750651 B1 KR101750651 B1 KR 101750651B1 KR 1020160010963 A KR1020160010963 A KR 1020160010963A KR 20160010963 A KR20160010963 A KR 20160010963A KR 101750651 B1 KR101750651 B1 KR 101750651B1
Authority
KR
South Korea
Prior art keywords
drug
injection device
intraocular
eyeball
present
Prior art date
Application number
KR1020160010963A
Other languages
Korean (ko)
Inventor
박철용
Original Assignee
동국대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동국대학교 산학협력단 filed Critical 동국대학교 산학협력단
Priority to KR1020160010963A priority Critical patent/KR101750651B1/en
Priority to PCT/KR2017/000205 priority patent/WO2017131356A1/en
Application granted granted Critical
Publication of KR101750651B1 publication Critical patent/KR101750651B1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0007—Special media to be introduced, removed or treated introduced into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0612—Eyes

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to an intraocular drug injection device, and more particularly, to an intraocular drug injection device including a drug chamber part capable of repeatedly charging a drug, a filter part capable of preventing a bacterial infection, and a drug moving part, The present invention relates to an intraocular drug injection device capable of efficiently delivering a drug into the eyeball by minimizing the residual rate of the drug through simplification of the structure.
Therefore, through the intraocular drug injection device according to the present invention, it is possible to easily perform the operation in the hospital, effectively prevent the side effects caused by the intravitreal injection treatment, and deliver the drug into the eyeball. And the like.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an intraocular drug injection device having a drug remotely intelligent function and a recharge function,

The present invention relates to an intraocular drug injection device, and more particularly, to a device for injecting a drug into an eyeball, which minimizes the residual rate of the drug in the device by effectively injecting the injection fluid into the eyeball, To a rechargeable intraocular drug injection device.

Some diseases and diseases of the eye after the eyeball are a threat to sight. Macular degeneration, choroidal neovascularization, retinopathy, retinitis, uveitis, macular edema, glaucoma, and neuropathy are some examples.

Conventional macular edema was treated with laser-assisted photocoagulation, vitrectomy, systemic administration, intravitreal administration of steroids, and sub-tenon administration. Photocoagulation by laser irradiation reduces macular edema by blocking blood vessels that leak. However, care must be taken to avoid extremely weak fovea during laser irradiation. If the central vein is injured by this procedure, the central visual field may be damaged. Also, multiple laser procedures are often needed to remove the swelling. Although vitrectomy is used when laser surgery is ineffective, this method is often associated with the potential for high tissue invasiveness that can lead to postoperative complications. In addition, steroid administration has been reported to be useful. Although systemic administration of steroids is possible to treat eye disease, it usually causes too serious side effects in scientific applications. Intra-vitreal administration and subtenon administration are therefore being studied. Although intravitreal administration can solve some problems associated with systemic administration, intravitreal administration of currently used ophthalmic compositions can cause ocular hypertension, steroidal glaucoma, and posterior capsular cataracts when steroids are administered. In addition, intravitreal administration of steroids sometimes causes postoperative complications. Subtenon is frequently used in clinical practice to reduce the possibility of invasion of the intravitreal tissue and patient burden. Compared with vitrectomy, steroid administration reduces the likelihood of invasion of the tissue, but this method is still associated with postoperative complications.

Particularly, injection therapy for macular edema, a monoclonal antibody preparation, should be injected into the eye using a needle (30G), which is about 0.5 ml per month or every few months, as a typical treatment for the geriatric macular edema. Patients were afraid of injections, and more and more phobias were observed with repeated injections. The injection therapy is often repeated several times to 100 times or more, and repeated injections are known to increase complications such as pain, vitreous hemorrhage, endophthalmitis, elevated intraocular pressure, and retinal detachment. Therefore, in order to provide better ocular therapy, researchers have proposed various implants for topical delivery of therapeutic agents to the eye.

Therefore, the development of a device for effective drug delivery into the eyeball has been the subject of major researches in order to treat some diseases of the eyeball including the macular edema of the senescent eye. -2006-0082792), but it is still not enough.

SUMMARY OF THE INVENTION The present invention has been conceived to solve the problems as described above. The present invention provides a device for injecting a drug into the eyeball, which is capable of being recharged and has a drug moving part capable of minimizing the residual amount of the drug, Invented.

SUMMARY OF THE INVENTION Accordingly,

A drug chamber part 100 on which the drug to be delivered is carried;

A drug moving part 200 disposed below the drug chamber part 100 and providing space for delivery of the drug into the eyeball through the scleral film; And

And a filter unit (300) disposed between the drug chamber part (100) and the drug transfer part (200) to remove bacteria.

However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.

In order to achieve the above object,

A drug chamber part 100 on which the drug to be delivered is carried;

A drug moving part 200 disposed below the drug chamber part 100 and providing space for delivery of the drug into the eyeball through the scleral film; And

And a filter unit (300) disposed between the drug chamber part (100) and the drug movement part (200) to remove bacteria.

Preferably, the drug chamber part 100 may further include a coating part 400 for covering the outer circumference to prevent exposure to the conjunctiva.

The drug chamber part 100 may include a drug injection part 110 formed on the upper part of the drug chamber part 100 and capable of penetrating the drug injection device.

Preferably, the drug transfer unit 200 includes a discharge unit 210 formed at a lower portion thereof for discharging the drug into the eyeball.

Preferably, the material of the coating portion 400 is formed of a material selected from the group consisting of silicon, ceramic, polyether urethane, azoic acid polymerized with polydimethylsiloxane, and a copolymer of styrene and polyamine .

The intraocular drug injection device according to the present invention includes a rechargeable drug chamber portion, a filter portion for filtering bacteria, and a drug transfer portion, so that the drug can be delivered into the eye through the device without direct injection into the eye. That is, when the injection of the drug into the drug chamber is started, the bacteria are filtered through the filter unit that blocks the bacterial infection from the outside, and the filtered drug can be delivered into the eye through the drug transfer unit. Such a short-distance connection structure minimizes the remaining amount of the drug in the device, thereby effectively transferring the drug into the eyeball, thereby improving the therapeutic effect on diseases such as senile macular edema.

In addition, the intraocular drug injection device is expected to effectively prevent adverse effects such as phobia, bleeding, and elevated intraocular pressure (IOP) in patients undergoing intravitreal injection of intravitreal bevacizumab in the treatment of senile macular edema and the like.

1 is a perspective view of an intraocular drug injection device 10 according to an embodiment of the present invention.
2 is an exploded perspective view of an intraocular drug injection device 10 according to an embodiment of the present invention.
3 shows an internal state of the drug chamber part 100 in the intraocular drug injection device 10 according to an embodiment of the present invention.
FIG. 4 is a view illustrating a state of a coating unit 400 in which an outer periphery of an apparatus implanted in an eye is wrapped and coated in an intraocular drug injection device 10 according to an embodiment of the present invention.
FIG. 5 is a schematic view illustrating a process of injecting a drug into the eyeball using the intraocular drug injection device 10 according to an embodiment of the present invention.

Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings, in order that those skilled in the art can easily carry out the present invention. The shapes, sizes, ratios, angles, numbers, and the like disclosed in the drawings for describing the embodiments of the present invention are illustrative, and thus the present invention is not limited thereto. In the following detailed description of the preferred embodiments of the present invention, a detailed description of known functions and configurations incorporated herein will be omitted when it may make the subject matter of the present invention rather unclear. In the drawings, like reference numerals are used throughout the drawings.

In addition, in the entire specification, when a part is referred to as being 'connected' to another part, it may be referred to as 'indirectly connected' not only with 'directly connected' . Also, to "include" an element means that it may include other elements, rather than excluding other elements, unless specifically stated otherwise.

FIGS. 1 and 2 show a perspective view and an exploded perspective view of an intraocular drug injection device 10 according to an embodiment of the present invention. 1 and 2, an intraocular drug injection device 10 according to an embodiment of the present invention includes a drug chamber part 100, a drug movement part 200, and a filter part 300 And may further comprise a coating part 400. [0050]

The intraocular drug injection device 10 according to an embodiment of the present invention is positioned under the conjunctiva of the eye ciliary body plane portion so that the drug is injected into the drug chamber portion 100 and the injected drug is injected into the drug movement portion 200 ), And can be delivered into the eye. By adopting such a configuration, since the drug is injected from the drug chamber part 100 into which the drug is injected at a short distance from the drug transfer part 200, the residual amount of the drug in the device can be minimized. In addition, it is anticipated that in the treatment of eyeballs administered over a long period of time, the complications of the conventional intravitreal injection therapy can be minimized.

Hereinafter, each component constituting the intra-ocular drug injection device 10 according to an embodiment of the present invention will be described in detail.

The drug chamber part 100 is provided under the conjunctiva of the ciliary body plane so that when the drug is injected from the outside by using the drug injection mechanism, It is possible to prevent direct contact between the needle of the instrument and the eyeball, thereby preventing the eyeball from being damaged by the needle. In addition, the drug chamber part 100 may be formed in a flat elliptical hemispherical shape in accordance with the arc of the eyeball surface, but is not limited thereto, in order to be placed under the conjunctiva of the ciliary body plane. The material used to form the drug chamber part 100 may be silicone, parylene, acrylic, or the like having flexibility. More preferably, silicone may be used. However, it is not limited thereto. Further, the drug storage capacity of the drug chamber part 100 is preferably 0.1 ml to 0.5 ml, more preferably 0.3 ml, but is not limited thereto. Also, as shown in FIG. 3, the interior of the drug chamber part 100 may include an inclined surface for the flow of the drug. By including the inclined surface, when the drug carried in the drug chamber part 100 moves to the drug moving part 200 to be described later, the residual drug can be minimized and the remaining drug can be minimized, May be possible.

The drug injecting portion 110 is a portion contacting the actual drug injecting mechanism, and more specifically, the needle can penetrate the drug injecting portion 110 to inject the drug into the drug chamber portion 100. For this, the drug injection unit 110 is preferably formed on the drug chamber part 100 and is made of a flexible material so that it can be easily inserted. At this time, as the flexible material, silicon or parylene can be used, but it is not limited thereto. Since the drug injection unit 110 has a clearance by the needles of the drug injection mechanism, the needle can be penetrated and the drug can be injected into the drug chamber part 100. [ On the other hand, when the injection of the drug is terminated and the drug injection mechanism is separated from the drug injection unit 110, the gap that has been pierced can be closed and closed by itself. At this time, the drug injector may use a syringe, but is not limited thereto.

As shown in FIGS. 1 and 2, the drug moving unit 200 is disposed below the drug chamber unit 100, and transmits the drug injected from the drug chamber unit 100 through the sclera into the eyeball It is possible to provide space for the user. At this time, the drug moving part 200 may be formed as a hollow cylindrical shape in order to directly penetrate the sclera, and the lower part may be in the form of a tip, but is not limited thereto. In addition, the drug moving part 200 is preferably made of a biocompatible material because it penetrates the sclera and is in direct contact with the eye tissue. Examples of the biocompatible material include, but are not limited to, parylene, polyetheretherketone (PEEK), polyethylene, polyimide, ethylene vinyl acetate, acrylic polymer, or a combination thereof. Further, it is preferable that the drug moving unit 200 can select a length depending on the thickness of the sclera of the patient. For example, the length of the drug moving part 200 may be 10 mm to 12 mm, but is not limited thereto.

As shown in FIG. 4, the discharge unit 210 may be formed at a lower portion of the drug moving unit 200 to transmit the drug into the eyeball. In this case, the medicament may flow into the eyeball through the drug transfer unit 200, and the intraocular fluid may flow into the drug transfer unit 200 through the discharge unit 210. This allows the medicament and intraocular fluid to be mixed in the drug transfer part 200 and can be discharged through the diffusion into the eye, thereby minimizing the residual drug in the device.

As shown in FIG. 2, the filter unit 300 is disposed between the drug chamber unit 100 and the drug transfer unit 200 to remove bacteria, Foreign substances such as bacteria can be filtered out, and infection of eyeballs caused by bacteria can be prevented.

On the other hand, in the case of conventional devices for delivering drugs into the eyeball, the device was placed in a considerably rearward position of the eyeball to prevent exposure of the device when implanted in the eyeball. As a result, there was a difficulty in introducing additional drugs, and complicated operations were performed when inserting and removing the device. Therefore, in order to solve such a problem, the intraocular drug injection device 10 according to the embodiment of the present invention is placed under the conjunctiva of the ciliary body plane, and the exposed device is coated with the coating part 400, Thereby preventing the side effects caused by the exposure of the device. Also, when removing the device, it can be easily removed by pulling the screw through a small incision.

As shown in FIG. 4, the coating unit 400 may prevent exposure to the outside of the conjunctiva by surrounding the outer circumference of the drug chamber 100, as shown in FIG. 4, to prevent side effects caused by exposure of the apparatus . The coating part 400 is preferably made of a biologically compatible material. Examples of the biologically suitable material include, but are not limited to, silicone, ceramic, polyether urethane, aboric acid polymerized with polydimethylsiloxane, or a copolymer of styrene and polyamine. In addition, the coating layer 400 may be formed of a transparent material to position the device when the drug is injected into the drug chamber 100.

FIG. 5 is a schematic view illustrating a process of injecting a drug into the eyeball using the intraocular drug injection device 10 according to an embodiment of the present invention. 5, in order to use the intraocular drug injection device 10 according to an embodiment of the present invention, the intraocular drug injection device 10 is first placed under the conjunctiva of the ciliary body plane, Thereby exposing the chamber part 100. This makes it possible to prevent the needle of the drug infusion device from contacting the eyeball and damaging the eyeball when the drug is injected through the drug injection device. Thereafter, the needle of the drug infusion device is injected into the drug chamber part 100 through the drug injection part 110 formed in the upper part of the drug chamber part 100, Is injected and held. When the injection of the drug is finished, the needle of the drug injection device is separated from the drug chamber part 100. At this time, the gap through which the drug injecting unit 110 has penetrated can be closed by itself. The drug is moved to the filter part 300 by the inclined surface in the drug chamber part 100 and the foreign substance such as bacteria is filtered out from the filter part 300. The filtered drug immediately spreads to the drug moving part 200 and diffuses into the eye through the discharging part 210 while the inner eye liquid flows into the drug moving part 200 through the discharging part 210 . In the process, the drug and the intraocular fluid are mixed, so that all drugs can spread into the eyeball. This minimizes the residual drug in the device and minimizes the remaining drug can minimize the difference between the desired dose and the actual amount reaching the eyeball so that the drug can be effectively injected into the eyeball. In addition, since the residual drug in the device can be minimized, denaturation due to mixing between drugs can be prevented even when a new drug is injected, and the drug can be recharged. Through this, it is possible to use various therapeutic agents after transplantation in a patient having various diseases of the eye after various ocular diseases, so that the treatment can be effectively performed and long-term treatment is possible.

It will be understood by those skilled in the art that the foregoing description of the present invention is for illustrative purposes only and that those of ordinary skill in the art can readily understand that various changes and modifications may be made without departing from the spirit or essential characteristics of the present invention. will be. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive.

10: Intraocular drug injection device according to one embodiment of the present invention
100: drug chamber part 110: drug injection part
200: drug moving part 210: discharging part
300: filter part 400: coating part

Claims (5)

In an intraocular drug injection device,
A drug chamber part 100 on which the drug to be delivered is carried;
A drug moving part 200 disposed below the drug chamber part 100 and providing space for delivery of the drug into the eyeball through the scleral film;
A filter unit 300 disposed between the drug chamber unit 100 and the drug transfer unit 200 to remove bacteria; And
And a coating part (400) for covering the outer circumference of the drug chamber part (100) to prevent exposure to the outside of the conjunctiva.
delete The intraocular drug injection device according to claim 1, wherein the drug chamber part (100) is formed on the upper side and includes a drug injection part (110) through which a drug injection device can be inserted.
The intraocular drug injection device according to claim 1, wherein the drug moving part (200) includes a discharge part (210) formed at a lower portion and discharging the drug into the eyeball.
The method of claim 1, wherein the material of the coating portion (400) is selected from the group consisting of silicon, ceramic, polyether urethane, azoic acid polymerized with polydimethylsiloxane, and copolymers of styrene and polyamine Wherein the medicament is injected into the eye.
KR1020160010963A 2016-01-28 2016-01-28 Intraocular drug injection device having a drug residue prevention and a refill function KR101750651B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020160010963A KR101750651B1 (en) 2016-01-28 2016-01-28 Intraocular drug injection device having a drug residue prevention and a refill function
PCT/KR2017/000205 WO2017131356A1 (en) 2016-01-28 2017-01-06 Device for injecting drug in eyeball, having residual drug prevention capability and recharging function

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160010963A KR101750651B1 (en) 2016-01-28 2016-01-28 Intraocular drug injection device having a drug residue prevention and a refill function

Publications (1)

Publication Number Publication Date
KR101750651B1 true KR101750651B1 (en) 2017-06-23

Family

ID=59283503

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020160010963A KR101750651B1 (en) 2016-01-28 2016-01-28 Intraocular drug injection device having a drug residue prevention and a refill function

Country Status (2)

Country Link
KR (1) KR101750651B1 (en)
WO (1) WO2017131356A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100313268B1 (en) * 1993-02-26 2002-11-22 산텐 세이야꾸 가부시키가이샤 Biodegradable Scleral Plug
US20140296800A1 (en) 2013-03-28 2014-10-02 Forsight Vision4, Inc. Ophthalmic Implant for Delivering Therapeutic Substances

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883717B2 (en) * 2001-06-12 2011-02-08 Johns Hopkins University Reservoir device for intraocular drug delivery
KR20070035529A (en) * 2004-06-01 2007-03-30 벡톤 디킨슨 앤드 컴퍼니 Ocular implant and methods for making and using same
BRPI0923810A2 (en) * 2009-01-02 2015-07-14 Alcon Res Ltd In-Place Replenished Ophthalmic Implant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100313268B1 (en) * 1993-02-26 2002-11-22 산텐 세이야꾸 가부시키가이샤 Biodegradable Scleral Plug
US20140296800A1 (en) 2013-03-28 2014-10-02 Forsight Vision4, Inc. Ophthalmic Implant for Delivering Therapeutic Substances

Also Published As

Publication number Publication date
WO2017131356A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
JP4261343B2 (en) Ophthalmic drug administration device
GB2548988B (en) Ophthalmic delivery device
JP4685311B2 (en) Ophthalmic drug delivery device
AU2002319606B2 (en) Ophthalmic drug delivery device
JP5896966B2 (en) Reservoir device for intraocular drug delivery
KR100732262B1 (en) Drug delivery device
US8545554B2 (en) Intraocular injector
US20060258994A1 (en) Implantable delivery device for administering pharmacological agents to an internal portion of a body
US20070092570A1 (en) Drug delivery device
AU2002319596A1 (en) Ophthalmic drug delivery device
JP2003518987A (en) Guide means for intraocular injection
CA2689424A1 (en) Methods for treatment and/or prevention of retinal disease
AU7854800A (en) Sub-tenon drug delivery
WO2008073576A1 (en) Drug delivery device
KR101750651B1 (en) Intraocular drug injection device having a drug residue prevention and a refill function
CN109431678B (en) Transscleral drug delivery system

Legal Events

Date Code Title Description
E701 Decision to grant or registration of patent right
GRNT Written decision to grant